We aimed to investigate the expression of the activation markers CD40 and CD71 across peripheral B cell subsets in individuals with radiologically isolated syndrome (RIS), and compare them to those with clinically isolated syndrome or MS (CIS/MS) and healthy controls (HC). The gene discussed is TFRC; the disease is in situ carcinoma.